Janux Therapeutics (JANX) Leases (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Leases data on file, last reported at $17.9 million in Q1 2026.

• Quarterly Leases fell 5.34% year-over-year to $17.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.9 million (down 5.34% YoY) and the FY2025 annual result came in at $18.4 million, down 4.58% from the prior year.
• Leases fell to $17.9 million in Q1 2026 per JANX's latest filing, from $18.4 million in the prior quarter.
• Across five years, Leases topped out at $22.8 million in Q2 2022 and bottomed at $130000.0 in Q1 2022.
• The 5-year median for Leases is $20.1 million (2024), against an average of $19.1 million.
• The widest annual swing landed in 2023, when Leases surged 16766.92%; it then dropped 8.04% in 2025.
• Tracing JANX's Leases over 5 years: stood at $22.3 million in 2022, then slipped by 6.47% to $20.8 million in 2023, then dropped by 7.45% to $19.3 million in 2024, then dropped by 4.58% to $18.4 million in 2025, then slipped by 2.89% to $17.9 million in 2026.
• Per Business Quant, the three latest JANX Leases figures stand at $17.9 million (Q1 2026), $18.4 million (Q4 2025), and $18.9 million (Q3 2025).

Peer Comparison